Table 2.
Polymeric Nanocarriers Obtained and Characterized in vivo for Delivery of More Than One Chemotherapeutic
| Nanocarriers | Drug | Route of Administration | Animal Model | Targeting |
|---|---|---|---|---|
| PLGA nanocarriers142 | Doxorubicin; berberine | i.v. | Healthy Sprague- Dawley rats | – |
| Poly(methyl vinyl ether-co-maleic anhydride) nanocarriers143 | Doxorubicin; selol | i.v. | Tumor-bearing BALB/c mice after subcutaneous injection of 4T1 (mouse mammary carcinoma) cells | – |
| PLGA nanocarriers144 | Oxaliplatin, irinotecan, and 5-fluorouracil | i.v. | Tumor-bearing BALB/c (nu/nu) nude mice after subcutaneous injection of SW1990 or Panc-1 (human pancreatic cancer) cells | – |
| PEGylated lipid bilayer coated mesoporous silica nanocarriers145 | Paclitaxel; curcumin | i.v. | Tumor-bearing BALB/c nude mice after subcutaneous injection of CIPp (canine breast cancer) cells | – |
| PLGA nanocarriers146,147 | Paclitaxel; perfluorooctyl bromide | i.v. | Tumor-bearing Fox1nu (nu/nu) mice after subcutaneous injection of CT-26 (murine colon cancer) cells | – |
Abbreviations: i.v., intravenous; PEG, poly(ethylene glycol); PLGA, poly(lactide-co-glycolide).